Tirzepatide Delivers Up to 21% Weight Loss in Obesity
SURMOUNT-1 establishes the first dual GIP/GLP-1 receptor agonist as a high-efficacy antiobesity agent, achieving weight reductions approaching bariatric surgery in adults without diabetes.
Tirzepatide delivers unprecedented weight loss results in obesity management.
Obesity significantly impacts global health, and effective treatments are crucial for reducing related morbidity and mortality. Tirzepatide led to weight reductions of -15.0%, -19.5%, and -20.9% for 5 mg, 10 mg, and 15 mg doses, respectively, compared to -3.1% with placebo over 72 weeks. This phase 3 trial supports tirzepatide as an effective obesity treatment, although gastrointestinal side effects should be managed, especially during dose escalation. Tirzepatide shows promise as a significant weight reduction option for obesity management.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators
Citation:Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.